---
schema_version: "secwatch.filing_event.v1"
accession: "0001267602-23-000050"
form_type: "8-K"
ticker: null
cik: "0001267602"
company_name: "ALIMERA SCIENCES INC"
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T20:53:12.920050+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alimera acquires U.S. rights to YUTIQ from EyePoint for $75M; projects $100M revenue in 2024

## Summary
- Upfront payment of $75M plus $7.5M guaranteed quarterly payments in 2024; royalties from 2025 at mid-to-low double digits on US net sales above thresholds starting $70M.
- Concurrent $69M equity raise via Series B Preferred and common stock; $20M additional term loan from SLR.
- Alimera projects at least $100M consolidated net revenue and >$20M Adjusted EBITDA in 2024.
- Board changes: Dr. Garheng Kong resigned; Jason Werner (Velan designee) appointed to Board.

## SEC filing metadata
- accession: 0001267602-23-000050
- form_type: 8-K
- cik: 0001267602
- company_name: ALIMERA SCIENCES INC
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/alim-20230516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001267602-23-000050
- JSON: https://secwatch.observer/filing/0001267602-23-000050.json
- Plain text: https://secwatch.observer/filing/0001267602-23-000050.txt

## Key facts
- Governance Changes
  ALIMERA SCIENCES INC: Filed Certificate of Amendment authorizing additional Series B Preferred Stock shares and changes to that series (effective 2023-05-16).
  - Change: charter amendment
  - Effective: 2023-05-16
  source text: In connection with the Tranche 2 Closing, on May 16, 2023, Alimera filed the Certificate of Amendment with the Secretary of State of the State of Delaware authorizing the additional shares of Series B Preferred Stock and the changes to such series described in Item 1.01.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm
- M&A Transactions
  ALIMERA SCIENCES INC completed an acquisition involving EyePoint Pharmaceuticals, Inc. for $75 million upfront payment plus four quarterly guaranteed payments totaling $7.5 million during 2024 and royalties (closed 2023-05-17).
  - Action: acquisition
  - Counterparty: EyePoint Pharmaceuticals, Inc.
  - Consideration: $75 million upfront payment plus four quarterly guaranteed payments totaling $7.5 million during 2024 and royalties
  - Closing: 2023-05-17
  source text: (“ Alimera ” or the “Company”) entered into a product rights agreement (the “ Product Rights Agreement ”) with EyePoint Pharmaceuticals, Inc. (“ EyePoint ”) whereby Alimera was granted an exclusive and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the “ License ”) under EyePoint’s and its affiliates’ interest in certain of EyePoint’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world, except Europe, the Middle East and Africa (the “ Licensed Territory ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm
- Material Agreements
  ALIMERA SCIENCES INC entered into Supply Agreement with EyePoint Pharmaceuticals, Inc..
  - Action: entry
  - Agreement: supply
  - Counterparty: EyePoint Pharmaceuticals, Inc.
  source text: In connection with the Transaction, Alimera entered into a commercial supply agreement (the “ Supply Agreement ”) with EyePoint
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm
- Material Agreements
  ALIMERA SCIENCES INC entered into Product Rights Agreement with EyePoint Pharmaceuticals, Inc. valued at $75 million (effective 2023-05-17).
  - Action: entry
  - Agreement: license
  - Counterparty: EyePoint Pharmaceuticals, Inc.
  - Value: $75 million
  - Effective: 2023-05-17
  source text: On May 17, 2023 (the “ Closing Date ”), Alimera Sciences, Inc. (“ Alimera ” or the “Company”) entered into a product rights agreement (the “ Product Rights Agreement ”) with EyePoint Pharmaceuticals, Inc. (“ EyePoint ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760223000050/0001267602-23-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.